Nitroxoline Market

The Nitroxoline market is projected to grow at a CAGR of 5.8% from 2025 to 2035, driven by the resurgence of interest in narrow-spectrum antibiotics, rising incidence of urinary tract infections (UTIs), and growing concern over antibiotic resistance. Nitroxoline is a hydroxyquinoline-based antibacterial agent that acts by chelating metal ions and inhibiting bacterial DNA synthesis. It is primarily used for the treatment of uncomplicated lower UTIs and exhibits strong activity against both Gram-positive and Gram-negative uropathogens, including E. coli, Enterococcus, and Proteus species.

Long available in European markets, Nitroxoline is gaining renewed attention for its efficacy in recurrent and resistant UTIs, particularly in patients where broad-spectrum antibiotics are no longer effective or preferred. It is also being investigated for potential use against biofilm-forming bacteria and even in non-urinary infections due to its antifungal and anti-biofilm activity. The drug’s low rate of resistance development, oral availability, and favorable safety profile make it an increasingly attractive option in outpatient care and antimicrobial stewardship programs.

Europe currently holds the largest share of the Nitroxoline market, due to long-standing approval, strong clinician familiarity, and increasing use in antibiotic rotation strategies. The Asia-Pacific region is expected to see the fastest growth, driven by high UTI prevalence, expanding access to healthcare, and rising awareness of drug-resistant infections. North America shows growing clinical interest in Nitroxoline as an alternative therapy, especially in recurrent UTI cases. Latin America and Africa also present steady growth opportunities through generic availability and public health campaigns for rational antibiotic use.